Reference   N Risk Ratio Measure Overall Risk Ratio (CI) Overall Risk Ratio (CI) of TC stratified by time since CM diagnosis
<10 years >10 years
Tucker et al., 1985† Total M F 3 2 1 RR 1.5 3.6 0.7 <1 year 7.0 0.0 10.3 1-4 years 1.8 5.8 0.0 5-9 years 0.0 0.0 0.0 >10 years 1.3 5.2 0.0
Glanzmann et al., 1992 Total 1 RR 1.8 (0.04-9.8)        
Ronckers et al., 2005† Total 78 RR 1.24 (0.98-1.55)        
Yang et al., 2011§     RR   2 mos-1 year 2.24 (1.07-4.12)* 1-5 years 1.41 (0.89-2.11) 5-9 years 1.42 (0.83-2.28) >10 years 0.84 (0.31-1.82)
Meta-Analysis Total 79 RR 1.49 (0.88-2.11)        
  Akslen et al., 1992 Total M F 8 5 3 SIR 1.32 (0.57-2.61) 4.17 (1.3-9.72)* 0.62 (0.13-1.81)        
Rubino et al., 2003 Total 25 SIR 2.5 (1.6-3.7)*        
Berthe et al., 2004 M F 1 1 SIR 7.14 (0.8-40) 1.30 (0.3-7.23)        
Canchola et al., 2006 Total 21 SIR 2.1 (1.3-3.2)* 2 mos-1 year 3.9 (1.4-8.4)* 1-3 years 2.3 (0.9-4.7) 3-5 years 2.1 (0.7-5.0) ≥5 years 0.9 (0.2-2.7)  
Sandeep et al., 2006† Total 81 SIR 1.09 (0.86-1.35) <1 year 1.86 (0.93-3.33) 1-9 years 1.07 (0.76-1.45) >10 years 0.96 (0.65-1.37)
Goggins et al., 2006† Total 79 SIR 1.25 (0.99-1.56) ≤3 years 1.63 (1.05–2.43)* 3-10 years 1.20 (0.81–1.71) >10 years 1.06 (0.69–1.56)
Brown et al., 2008‡ Total M F 89 57 32 SIR 1.17 (0.94-1.44) 1.13 (0.86-1.47) 1.24 (0.85-1.75)        
Meta-Analysis Total M F 224 89 35 SIR 1.49 (1.20-1.79)* 1.44 (0.90-1.98) 0.84 (0.41-1.26)        
Oakley et al., 2014† Total 78 OR 1.8 (1.4-2.3)*        
TC, Thyroid cancer; CM, cutaneous melanoma; N, number; M, males; F, females; RR, relative risk; OR, odds ratio; SIR, standardized incidence ratio; CI, 95% confidence interval; mos, months; *RR/SIR/OR differs significantly from 1 (p < 0.05); †These studies also analyzed RR/SIR/OR of TC subsequent to CM and are included in Table IIa; ‡This study also analyzed effect of age at TC diagnosis in development of subsequent CM; §This study reported RR for patients over 45 years at age of primary TC diagnosis.
Table 2b: Risk of cutaneous melanoma (CM) after thyroid cancer (TC).